PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsOvarian cancer drug could treat BRCA-related breast cancer

BioNews

Ovarian cancer drug could treat BRCA-related breast cancer

Published 30 June 2017 posted in News and appears in BioNews 904

Author

Dr Loredana Guglielmi

PET BioNews

A drug treatment for ovarian cancer has shown success against inherited breast cancer...

A drug treatment for ovarian cancer has shown success against inherited breast cancer.

Patients showed improved survival and decreased disease relapse after receiving olaparib, a drug used to treat ovarian cancer in women who carry BRCA1 or BRCA2 mutations.

'It is a perfect example of how understanding a patient's genetics and the biology of their tumour can be used to target its weaknesses and personalize treatment,' said Professor Andrew Tutt, director of the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, who was not involved in the study. 'Olaparib is already available for women with BRCA-mutant advanced ovarian cancer, and is the first drug to be approved that is directed against an inherited genetic mutation.'

Olaparib belongs to a class of drugs called PARP-inhibitors that act against proteins involved in DNA repair. Inherited BRCA mutations, which occur in up to three percent of all breast cancers, can impair the normal function of DNA repair by favouring abnormal cell growth, and so increase the risk of cancer.

In the OlumpiAD trial, carried out at the Memorial Sloan Kettering Cancer Center, New York, olaparib was given to 302 women who had metastatic breast cancer caused by BRCA mutations. The treatment led to tumour shrinkage in 60 percent of women, compared with only 29 percent of those treated with standard chemotherapy. After a median follow-up of 14 months, 42 percent of women showed slower cancer progression.

Researchers said the results were too preliminary to state whether patients could really benefit from olaparib treatment in terms of extended life. However, side effects such as hair loss and low white blood cell counts were reduced and only 37 percent of the patients experienced serious side effects compared with 50 percent for chemotherapy, demonstrating a better health-related quality of life.

'This is the first demonstration of improved outcomes with a PARP inhibitor compared to standard treatment in women with BRCA mutation-associated breast cancer,' said lead study author Dr Mark Robson of Memorial Sloan Kettering Cancer Center, New York. 'It is especially encouraging to see that olaparib was effective against triple negative breast cancers that arise in women with inherited, germline BRCA mutations. This type of breast cancer is particularly difficult to treat and often affects younger women.'

The results were published in the New England Journal of Medicine and presented at the 2017 American Society of Clinical Oncology Annual Meeting.

AstraZeneca expects to seek approval for use of the drug in breast cancer toward the end of this year, and two more trials will investigate potential applications of olaparib in patients with other types of breast cancer.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 May 2021 • 2 minutes read

PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations

by Emma Bunting

New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...

PET BioNews
News
25 May 2018 • 1 minute read

Virus trained to attack ovarian cancer cells

by Martha Henriques

A virus has been reprogrammed to attack ovarian cancer cells in mice, effectively destroying tumours...

PET BioNews
News
18 May 2018 • 2 minutes read

Breast cancer drug works in half the time

by Christie Whitehouse

A new study indicates that an important drug used to treat breast cancer is just as effective when the course of treatment is shortened by half.

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 May 2018 • 2 minutes read

CRISPR study finds resistance mutations to key cancer drugs

by Hannah Tippett Simpson

DNA mutations that give tumours resistance to a new class of breakthrough breast and ovarian cancer drugs have been discovered...

PET BioNews
News
4 May 2018 • 2 minutes read

DNA test may benefit women with hard-to-treat breast cancer

by Dr Jamie Heather

Genetic testing could reveal a subset of patients with aggressive breast cancer who would benefit from a non-standard treatment, a clinical trial has found...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 June 2017 • 2 minutes read

FDA gives go-ahead to first cancer drug based on genetics

by Shaoni Bhattacharya

The first cancer drug based on a specific genetic feature has been approved by the US drugs regulator...

PET BioNews
News
20 March 2017 • 2 minutes read

Existing drugs could benefit one in five breast cancer patients

by Dr Molly Godfrey

A genetic study of breast cancer patients suggests that existing drugs for treating rare breast and ovarian cancers may help more patients than previously thought...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 July 2016 • 3 minutes read

BRCA mutations linked to prostate and uterine cancers

by Dr Antony Starza-Allen

Genetic mutations on several genes including BRCA2 have been associated with prostate cancer; while in a separate study, a BRCA1 mutation has been linked to a particular form of uterine cancer...

PET BioNews
News
15 July 2016 • 2 minutes read

Gene-targeted ovarian cancer drug also treats prostate cancer

by Dr Jane Currie

A drug that targets genetic mutations in ovarian cancer has been found to work in men with prostate cancer with similar mutations, according to a new study...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 July 2009 • 2 minutes read

Hope for new drug to treat inherited breast, ovarian and prostate cancers

by Dr Rebecca Robey

A new drug for the treatment of inherited forms of breast, ovarian and prostate cancer has shown promising results in early clinical trials. The study, published in the New England Journal of Medicine, reported that the drug promoted tumour reduction and clinical improvement in advanced-stage cancer patients whilst causing fewer side effects than conventional chemotherapy....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Two blood cancers treated successfully with immunotherapy

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856